2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

RSV infection

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

5

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99586
    Suptavumab

    REGN2222

    		 RSV Infection
    Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
    Suptavumab
  • HY-P99756
    Nirsevimab

    MEDI8897

    		 RSV Infection
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
    Nirsevimab
  • HY-P9944
    Palivizumab

    MEDI 493

    		 RSV Infection Inflammation/Immunology Cancer
    Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
    Palivizumab
  • HY-P99804
    Clesrovimab

    MK1654

    		 RSV Infection
    Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection .
    Clesrovimab
  • HY-109004
    Enzaplatovir

    BTA-C585

    		 RSV Infection
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection .
    Enzaplatovir
  • HY-130626
    RSV/IAV-IN-1

    		RSV Influenza Virus Infection
    RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .
    RSV/IAV-IN-1
  • HY-130627
    RSV/IAV-IN-2

    		RSV Influenza Virus Infection
    RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .
    RSV/IAV-IN-2
  • HY-163773
    RSV-IN-13

    		RSV Infection
    RSV-IN-13 (compound 5c) exhibits antiviral activity against RSV with an EC50 value of 0.78 nM. RSV-IN-13 can be used in the study of respiratory tract infections .
    RSV-IN-13
  • HY-163567
    RSV-IN-10

    		RSV Infection
    RSV-IN-10 (compound 6a) shows antiviral activity against RSV with the IC50 of 4 μM. RSV-IN-10 can be used for study of respiratory infection .
    RSV-IN-10
  • HY-163568
    RSV-IN-11

    		RSV Infection
    RSV-IN-11 (compound 10b) shows antiviral activity against RSV with the IC50 of 6.32 μM. RSV-IN-10 can be used for study of respiratory infection .
    RSV-IN-11
  • HY-154968
    RSV L-protein-IN-5

    		RSV Infection
    RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC50=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-5
  • HY-115574
    RSV L-protein-IN-1

    		RSV Infection
    RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-1
  • HY-168616
    CL-A3-7

    		RSV IGF-1R Infection
    CL-A3-7 is a virus-cell fusion inhibitor targeting the RSV F protein. It exerts its effect by blocking the interaction between the virus and the host IGF1R, effectively inhibiting infections of both wild-type RSV and the K394R variant. It is applicable to anti-RSV drug development and resistance-related research .
    CL-A3-7
  • HY-114721
    BTA-9881

    MEDI-564

    		 RSV Infection
    BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC50: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property .
    BTA-9881
  • HY-109004A
    (S)-Enzaplatovir

    (S)-BTA-C585

    		 RSV Cancer
    (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77) .
    (S)-Enzaplatovir
  • HY-P99209
    Motavizumab

    MEDI-524

    		 RSV Infection
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
    Motavizumab
  • HY-161877
    GS-7682

    		RSV Infection
    GS-7682 is an antiviral compound. GS-7682 has inhibitory activity against pneumoviruses and picornaviruses. GS-7682 can be used in the study of respiratory diseases such as asthma and chronic obstructive pulmonary disease .
    GS-7682

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: